Safety Results From Auris Medical AG's Clinical Development of AM-101 Presented at International Conference
5/17/2013
More...
|
Pearl Therapeutics Presents Dose-Ranging, Efficacy and Safety Results of PT003 as well as Components, PT001 and PT005 at American Thoracic Society Meeting
5/17/2013
More...
|
New Data to be Presented at the 2013 American Society of Clinical Oncology Annual Meeting Show Active Biotech AB (BTPC)'s Commitment to Oncology Research
5/16/2013
More...
|
Verona Pharma to Present Clinical and Pre-Clinical Data Highlighting the Significant Bronchodilator Activity of Novel Dual PDE3/4 Inhibitor RPL554 at Upcoming American Thoracic Society International Conference
5/16/2013
More...
|
Gradalis Inc. Release: FANG™ Personalized Tumor Vaccine Stimulates Immune Response and More than Doubles Time to Recurrence in Patients with Advanced Stage Ovarian Cancer
5/16/2013
More...
|
GENFIT Corp. (ALGFT) Release: GFT505 Reduces the Risk of Cardiovascular Events Through Its Action on Remnant Cholesterol
5/15/2013
More...
|
Sangamo BioSciences, Inc. (SGMO) Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic®, SB-728-T
5/15/2013
More...
|
Plandai Biotechnology, Inc. (PLPL.OB) Announces Positive Anti-Malaria Test Results Using Phytofare™ Extract
5/15/2013
More...
|
Syndax Pharmaceuticals Inc. Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
5/14/2013
More...
|
Inovio Pharmaceuticals (INO) DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
5/14/2013
More...
|
MorphoSys AG Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non- Hodgkin's Lymphoma
5/13/2013
More...
|
Zalicus Inc. (ZLCS) Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain
5/10/2013
More...
|
BioTie Therapies Corp. Announces Start of Clinical Study With Nepicastat (SYN117) in Cocaine Dependence
5/10/2013
More...
|
Lexicon Pharmaceuticals, Inc. (LXRX) Advances LX4211 In Type 1 Diabetes Phase 2 Trial
5/10/2013
More...
|
Creabilis SA Announces Headline Results of Its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327
5/10/2013
More...
|
Izun Pharmaceuticals Initiates Additional Oral Mucositis Trial Sites
5/9/2013
More...
|
Jennerex, Inc. Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)
5/9/2013
More...
|
NeuralStem Inc. ALS Trial Investigator and Patient on Sirius XM
5/9/2013
More...
|
Idera Pharmaceuticals, Inc. (IDRA) Announces Presentation of Positive Data From Phase 2 Trial of TLR 7 and 9 Antagonist in Patients With Moderate-to-Severe Plaque Psoriasis
5/8/2013
More...
|
Anthera Pharmaceuticals, Inc. (ANTH) Announces Additional Data From Phase 2b PEARL-SC Blisibimod Study
5/8/2013
More...
|
PAION AG Release: Recruitment of Phase II/III Study With Short-Acting Anaesthetic/Sedative Remimazolam (Ono's Development Code: ONO-2745) in Japan is Completed
5/8/2013
More...
|
FDA Grants Breakthrough Status to Johnson & Johnson (JNJ), Genmab A/S (GEN.CO) Cancer Drug
5/7/2013
More...
|
Opsona Therapeutics Ltd. Initiates a Phase II Study With OPN-305, a First-in Class Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
5/7/2013
More...
|
Scioderm's SD-101 Receives Breakthrough Therapy Designation From FDA for Treatment of Epidermolysis Bullosa
5/6/2013
More...
|
Anavex Life Sciences Corp. (AVXL.OB) Invited to File Funding Application for Phase 2a Clinical Trial of ANAVEX 2-73
5/6/2013
More...
|
Senesco Technologies, Inc. (SNT) Announces Start of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma
5/6/2013
More...
|
CytRx Corporation (CYTR) Receives Recommendation From Data Safety Monitoring Committee to Complete International Phase 2b Trial With Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma
5/6/2013
More...
|
Isis Pharmaceuticals, Inc. (ISIS) Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients With Liver Cancer
5/6/2013
More...
|
Esperion Therapeutics, Inc. Presents Full Results of Phase 2 Clinical Trial Showing Its Novel Oral Therapy ETC-1002 Lowered LDL-C By Up to 43 Pct in Hypercholesterolemic Patients With Type 2 Diabetes
5/3/2013
More...
|
Allergan Inc. (AGN) Delays Drug That Would Rival Regeneron Pharmaceuticals, Inc. (REGN)'s Eylea
5/2/2013
More...
|
Antisense Therapeutics Limited (ANP.AX) Release: ATL1102 for Multiple Sclerosis -Toxicology Study to Commence
5/2/2013
More...
|
Positive Phase 2 Data From Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN)' Brain Cancer Vaccine Presented at Plenary Session of American Academy of Neurological Surgeons Meeting
5/1/2013
More...
|
Janssen Research & Development Release: Daratumumab Receives Breakthrough Therapy Designation in Double Refractory Multiple Myeloma From FDA
5/1/2013
More...
|
Clinical Results for Oramed Pharmaceuticals Inc. (ORMP.OB)'s Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
5/1/2013
More...
|
Omeros Corporation (OMER) Requests Fast Track Designation for OMS824 for the Treatment of Huntington's Disease
5/1/2013
More...
|
OncoGenex Pharmaceuticals Inc. Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination With ABRAXANE® Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
5/1/2013
More...
|
GTx, Inc. (GTXI) Initiating Phase 2, Open-Label Study of Enobosarm to Treat ER Positive Metastatic Breast Cancer
4/30/2013
More...
|
Immunicum Seeks Approval for a Clinical Phase I/II-Trial in Liver Cancer
4/30/2013
More...
|
OncoGenex Pharmaceuticals Inc. Announces That the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is Now Open for Enrollment
4/30/2013
More...
|
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Updated Phase 2 Survival Data of Sapacitabine for MDS
4/30/2013
More...
|
Cempra Pharmaceuticals, Inc. to Present Data on Solithromycin's (CEM-101) Potential Against Urogenital Infections and Multidrug-Resistant Pathogens at ECCMID
4/29/2013
More...
|
Targacept, Inc. (TRGT) Completes Recruitment in Phase 2b Trial of TC-1734 in Mild to Moderate Alzheimer's Disease
4/29/2013
More...
|
Chimerix, Inc. Presents at Annual EBMT Meeting: Antiviral Activity of CMX001 in Patients With Life-Threatening Viral Infections
4/29/2013
More...
|
Merrimack Pharmaceuticals Inc. Completes Enrollment of Second Cohort in Phase 2 Study of MM-121 in Non-Small Cell Lung Cancer
4/29/2013
More...
|
Verona Pharma Release: Clinical and Scientific Advisory Board Formed to Help Guide Future Development of RPL554
4/29/2013
More...
|
Monoclonal Antibody With Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
4/26/2013
More...
|
MorphoSys AG Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in B-cell Acute Lymphoblastic Leukemia
4/26/2013
More...
|
Medgenics, Inc. Reports "Encouraging" Data From Epodure Biopump Trial
4/25/2013
More...
|
AbbVie (ABBV) Hepatitis C Drugs Knock Out Virus at Eight Weeks
4/25/2013
More...
|
Top-Line Data Show AcelRx Pharmaceuticals (ACRX)' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
4/24/2013
More...
|
Achillion Pharmaceuticals, Inc. (ACHN) Says Hepatitis C Drug Subdues Virus in 63 Pct of Patients
4/24/2013
More...
|
Chimerix, Inc. Announces Final Study Design for Phase 3 SUPPRESS Trial of CMX001 for Prevention of CMV Infection
4/24/2013
More...
|
Vertex Pharmaceuticals Incorporated (VRTX) Booms on Cystic Fibrosis Combo Drug Study
4/23/2013
More...
|
Merck & Co., Inc. (MRK) to Present Updated Interim Data From Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™
4/23/2013
More...
|
Enanta Pharmaceuticals, Inc. Announces New Data From Phase 2b Interferon-Free Combination Studies With Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL
4/23/2013
More...
|
Nymox Pharmaceutical (NYMX) Announces First Patient Enrollment for NX02-0022 Reinjection Study of NX-1207 for BPH
4/23/2013
More...
|
Galapagos NV (GLPG.BR) Starts Phase 2A Study With GLPG0974 in Ulcerative Colitis
4/23/2013
More...
|
Halozyme Therapeutics, Inc. (HALO) Initiates Randomized Phase 2 Trial of PEGPH20 in Pancreatic Cancer
4/23/2013
More...
|
Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated With Post-Herpetic Neuralgia
4/23/2013
More...
|
Isis Pharmaceuticals, Inc. (ISIS) Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
4/23/2013
More...
|
Ceregene, Inc. Reports Data From Parkinson's Disease Phase 2b Study
4/22/2013
More...
|
Astellas Pharma Inc. (YPH.BE), GlaxoSmithKline (GSK) Vie to Make "High Altitude" Anemia Pill
4/22/2013
More...
|
Synta Pharmaceuticals Announces First Patients Treated in Pivotal GALAXY-2 Trial Evaluating Ganetespib in Advanced Non-Small Cell Lung Cancer
4/22/2013
More...
|
Galapagos NV (GLPG.BR) Discovers Novel Candidate Drug to Treat Breast Cancer
4/22/2013
More...
|
TiGenix: Positive Phase IIa Study Results in Refractory Rheumatoid Arthritis With Allogeneic Stem Cell Product Cx611
4/22/2013
More...
|
ViroPharma Incorporated (VPHM) Release: Treatment With VP20621 (Non-Toxigenic Clostridium difficile; NTCD) in a Phase 2 Study Resulted in High Rates of Colonization and Statistically Significant Reductions in Recurrence of C. difficile Infection
4/22/2013
More...
|
BioInvent (BOVNF) Initiates Clinical Trial With BI-505 in Smoldering Myeloma
4/22/2013
More...
|
Civitas Therapeutics Announces Positive Phase 2 Clinical Results for CVT-301
4/19/2013
More...
|
Navidea Biopharmaceuticals (NAVB) Announces That Results of NAV4694 Clinical Trial Published in the Journal of Nuclear Medicine
4/19/2013
More...
|
Targacept, Inc. (TRGT) Completes Recruitment in Phase 2b Schizophrenia Trial of TC-5619
4/18/2013
More...
|
StemCells Inc. (STEM) Adds Byers Eye Institute at Stanford as Second Site for Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
4/18/2013
More...
|
Savara Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
4/18/2013
More...
|
Resverlogix Corporation (RVX.TO) Completes Dosing in ASSURE Clinical Trial
4/18/2013
More...
|
Alkermes plc (ALKS) Has Jumped to a New High on Study Results
4/17/2013
More...
|
Immune Targeting Systems (ITS) Ltd. Announces Positive Phase 2a Data in the at Risk Elderly Population With Flunisyn™, Its Pan-Strain Influenza a T-Cell Vaccine, and Two UK Biomedical Catalyst Grants for Chronic Hepatitis B and Oncology
4/17/2013
More...
|
Advaxis, Inc. to Report 12-Month Survival From Its Phase 2 Study of ADXS-HPV in Women With Recurrent/Refractory Cervical Cancer
4/17/2013
More...
|
FDA Approves Phase II of Stem Cell Trial for ALS Led by University of Michigan's Dr. Eva Feldman
4/17/2013
More...
|
NeuralStem Inc. Receives FDA Approval to Commence Phase II Stem Cell Trial in Amytrophic Lateral Sclerosis
4/17/2013
More...
|
Chipscreen Biosciences Announces Achievement of Primary Endpoint in Chidamide Registrational Trial in China
4/16/2013
More...
|
Galapagos NV (GLPG.BR) Presents Scope of GLPG0634 Phase 2b Program
4/16/2013
More...
|
Rhythm Initiates Phase 2 Clinical Trial of Ghrelin Prokinetic RM-131 for Lower GI Functional Disorders
4/16/2013
More...
|
Benitec, Inc. (BLT.AX) Selects University of California, San Diego (UCSD) as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections
4/16/2013
More...
|
Acorda Therapeutics (ACOR) Drug Helps Stroke Patients Walk Better
4/15/2013
More...
|
Kythera Biopharmaceuticals Presents Positive Magnetic Resonance Imaging (MRI) Results From Phase IIb Study of ATX-101 in the Reduction of Submental Fat or "Double Chin"
4/15/2013
More...
|
Fibrocell Science, Inc. Autologous Fibroblast Injections Show Improvement in Facial Acne Scar Appearance
4/15/2013
More...
|
NeuroDerm Ltd. Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease
4/15/2013
More...
|
Galleon Pharmaceuticals, Inc. Demonstrates Successful Clinical Proof-of-Concept for Lead Product From Sleep Apnea Drug-Discovery Platform
4/11/2013
More...
|
Sorbent Therapeutics, Inc. Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients With Heart Failure
4/11/2013
More...
|
OncoGenex Pharmaceuticals Inc. Announces Plans for the Initiation of the Spruce™ Clinical Trial Evaluating OGX-427 in Combination With Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer
4/11/2013
More...
|
Early Results of Activartis Biotech GmbH AV0113 Cancer Immunotherapy in Glioblastoma Trial Reveal Promising Trend
4/11/2013
More...
|
GlaxoSmithKline (GSK) Muscular Dystrophy Drug Reaches Primary Objective in Study
4/10/2013
More...
|
Cell>Point Announces Encouraging Results From 99mTc-EC-G Phase 2a Trial in Evaluating Presence and Severity of Coronary Artery Disease
4/10/2013
More...
|
Reviva Pharmaceuticals Inc Reports Positive Top-Line Results From a Phase 2 Clinical Trial of RP5063 for the Treatment of Schizophrenia and Schizoaffective Disorder
4/10/2013
More...
|
PhotoCure Announces Positive Final Results of Phase 2b Cevira ® Study
4/10/2013
More...
|
SALVAT and Kwang Dong Pharmaceutical Announced Positive Results of Phase IIb for Tarafenacin for Overactive Bladder Treatment
4/10/2013
More...
|
Jennerex, Inc. Announces Presentation of Data Demonstrating Pexa-Vec's Vascular Targeting Mechanism
4/9/2013
More...
|
Vaxil Reports Positive Results From a Phase I/II Clinical Trial Using Its Therapeutic Cancer Vaccine, ImMucin, in Patients With Multiple Myeloma
4/9/2013
More...
|
Pharmacyclics, Inc. (PCYC) Release: Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
4/8/2013
More...
|
NovaBay Pharmaceuticals, Inc. (NBY) Global Ophthalmology Study Enrolls First Patients in Brazil
4/8/2013
More...
|
Trigemina Receives ISP Approval of Clinical Study Protocol for TI-001 Phase 2 Trial
4/8/2013
More...
|
Pharmacyclics, Inc. (PCYC) Announces Third Breakthrough Therapy Designation for Ibrutinib from the FDA
4/8/2013
More...
|
Spectrum Pharmaceuticals, Inc. (SPPI) Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced Neutropenia
4/8/2013
More...
|
Merrimack Pharmaceuticals Inc. Lung Cancer Drug Fails in One Mid-Stage Trial Group
4/5/2013
More...
|
Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) (SRPT) Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy
4/5/2013
More...
|
Novavax, Inc. (NVAX) Vaccine Meets Mid-Stage Trial Goal
4/4/2013
More...
|
The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Biogen Idec, Inc. (Massachusetts) (BIIB) Daclizumab HYP in Multiple Sclerosis
4/4/2013
More...
|
Hadasit Bio Holdings Flagship Portfolio Company Enlivex Therapeutics Ltd. Awarded Orphan Drug Status for ApoCell, Inc. Treatment by the FDA
4/4/2013
More...
|
Starpharma Holdings Ltd Release: VivaGel® Study Demonstrates Reduced Risk of Recurrent BV
4/4/2013
More...
|
P2 Study Shows Effectiveness of Axelar AB's AXL-003
4/3/2013
More...
|
PRANA Biotechnology (PRAN) Provides Clinical Trials Safety and Progress Update
4/3/2013
More...
|
Aspireo Pharmaceuticals Reports Somatoprim Phase IIa Proof of Concept Results in Acromegaly
4/3/2013
More...
|
NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
4/2/2013
More...
|
Inovio Pharmaceuticals (INO) Collaborator ChronTech Reports Interim Phase II Clinical Study Results From ChronVac-C Vaccine for Hepatitis C Infection
4/2/2013
More...
|
Isis Pharmaceuticals, Inc. (ISIS)'s apoC-III Shown to Significantly Reduce Triglycerides
4/1/2013
More...
|
Idera Pharmaceuticals, Inc. (IDRA) Announces Clinical Development Progress in Its Autoimmune Diseases Program
4/1/2013
More...
|
Oncolytics Biotech Inc. (ONC.TO)'s Lung Cancer Drug Meets Main Goal of Mid-Stage Study
3/29/2013
More...
|
Research Published in The New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S' Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials
3/28/2013
More...
|
Repros Therapeutics Inc. (RPRX) Testosterone Drug Hits Main Goals of Key Study
3/28/2013
More...
|
Insmed Incorporated (INSM) Release: ARIKACE Receives Orphan Drug Designation for Treating Infections Caused by Non-Tuberculous Mycobacteria
3/28/2013
More...
|
Oncolytics Biotech Inc. (ONC.TO) Meets Primary Overall Statistical Endpoint in U.S. Phase 2 Study of REOLYSIN® in Squamous Cell Lung Cancer
3/28/2013
More...
|
CureVac GmbH Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer
3/27/2013
More...
|
Lightlake Therapeutics Inc. (LLTP) Announces Phase II Clinical Trial Results of Treatment for Binge Eating Disorder Accepted at the American Psychiatric Association Annual Meeting
3/27/2013
More...
|
Navidea Biopharmaceuticals (NAVB) Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Subjects With Mild Cognitive Impairment (MCI)
3/27/2013
More...
|
Boston Therapeutics, Inc. Strategically Positioned to Focus Its Pipeline on Commercializing Pharmaceutical Drugs to Treat Diabetes and Inflammatory Disease: to Accelerate Commercialization of PAZ320 & IPOXYN™
3/27/2013
More...
|
Galapagos NV (GLPG.BR) to Start Phase 2a Study With GLPG0974 in IBD Patients
3/27/2013
More...
|
Neurocrine Biosciences, Inc. (NBIX) Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
3/27/2013
More...
|
Convergence Pharmaceuticals Announces Successful Interim Data From Ground-Breaking Phase II Trigeminal Neuralgia Study
3/27/2013
More...
|
Acceleron Pharma Receives Two FDA Orphan Designations for ACE-536
3/26/2013
More...
|
Cerulean Pharma Inc. Fails Phase 2b Lung Cancer Trial
3/25/2013
More...
|
OncoSec Medical Inc. Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
3/25/2013
More...
|
Auxilium Pharmaceuticals (AUXL) Announces Positive Top-Line Data From XIAFLEX®
3/25/2013
More...
|
GlaxoSmithKline (GSK)'s Malaria Vaccine Ineffective Over Time
3/22/2013
More...
|
Anthera Pharmaceuticals, Inc. (ANTH) Announces Data From the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
3/22/2013
More...
|
Benitec, Inc. (BLT.AX) Selects the Duke Clinical Research Unit as a Site for Hepatitis C Phase I/II Clinical Trial
3/22/2013
More...
|
MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.) Release: Menstrual Blood Stem Cells Used to Treat Heart Failure Patients
3/22/2013
More...
|
Addex Therapeutics (ADXN.SW) Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology
3/22/2013
More...
|
Summit Corporation Outlines Clinical Development Plans for Utrophin Modulator Program for Duchenne Muscular Dystrophy
3/21/2013
More...
|
Proteo Inc. (PTEO.OB) /Proteo Biotech AG (PTEO.OB): FDA Grants Orphan Drug Designation to Elafin for Prevention of Inflammatory Complications of Transthoracic Esophagectomy
3/21/2013
More...
|
Ohr Pharmaceutical (OHRP) Announces Results from OHR/AVR118 Phase II Trial in Cancer Cachexia
3/21/2013
More...
|
BrainStorm Cell Therapeutics Inc. Release: Results of NurOwn™ Clinical Trial Suggest Efficacy in ALS Patients
3/21/2013
More...
|
BioTie Therapies Corp. Presents Tozadenant Phase 2b Data at American Academy of Neurology Annual Meeting
3/21/2013
More...
|
Positive Results From Affinium Pharmaceuticals' Phase 2a Clinical Trial of AFN-1252 in ABSSSI
3/21/2013
More...
|
First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Inc.' Lead Therapeutic Candidate for Treatment of Migraine, ALD403
3/20/2013
More...
|
Ritter Pharmaceuticals, Inc. Encouraged by Meeting With FDA
3/20/2013
More...
|
FDA Deems Novartis AG (NVS) Lung Cancer Drug a "Breakthrough Therapy"
3/19/2013
More...
|
TheraVida, Inc. Presents Positive Phase 2 Data for Tolenix™ (THVD-201) in Patients With Overactive Bladder at the 28th Annual Congress of the European Urological Association
3/19/2013
More...
|
GTx, Inc. (GTXI)-758 Poster Presentation of Phase II Trial Data in Advanced Prostate Cancer Selected as One of the Best Posters at the 28th Annual European Association of Urology Congress
3/19/2013
More...
|
Taiwan Liposome Company's Liver Cancer Drug Put on Fast Track in China
3/19/2013
More...
|
MethylGene Reports Results of Phase 2 Trial of MGCD290
3/18/2013
More...
|
Merrimack Pharmaceuticals Inc. Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Paclitaxel in Patients With Platinum-Resistant or Refractory Advanced Ovarian Cancers
3/18/2013
More...
|
Phase II ALS Clinical Trial With BrainStorm Cell Therapeutics Inc.'s NurOwn™ to be Expanded to a Third Premiere U.S. Clinical Site
3/18/2013
More...
|
With Kythera Biopharmaceuticals as Model, Lithera Tests Drug to Shrink "Love Handles"
3/15/2013
More...
|
Trophos Launches First Study of Olesoxime in Multiple Sclerosis Patients
3/14/2013
More...
|
GTx, Inc. (GTXI) Release: Enobosarm Phase 2 Trial for Muscle Wasting and Physical Function in Patients With Cancer Published in The Lancet Oncology
3/14/2013
More...
|
Journal of Immunology Research: Vaccine Based Upon Heat Biologics' ImPACT Therapy Provides Significant Protection Against SIV Infection
3/14/2013
More...
|
The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnology AG’s CYT003 for the Treatment of Allergic Asthma
3/13/2013
More...
|
Immune Response BioPharma to Seek Orphan Designation of NeuroVax for Pediatric MS
3/13/2013
More...
|
Ceregene, Inc. and Alzheimer's Disease Cooperative Study Group Complete Enrollment of CERE-110 Phase 2 Trial
3/13/2013
More...
|
N30 Pharma Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
3/13/2013
More...
|
Biothera Completes Enrollment of Second Phase 2b Lung Cancer Trial
3/13/2013
More...
|
Orion Pharma's Alzheimer's Drug Add-On Brings Some Memory Improvement
3/12/2013
More...
|
Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat
3/12/2013
More...
|
FDA Grants Chimerix, Inc. Fast Track Designation for CMX001 for the Prevention of Clinically Significant Cytomegalovirus Infection
3/12/2013
More...
|
Telormedix Enrolls First Patient for Phase II in Bladder Cancer
3/11/2013
More...
|
Genmab, Inc. (GEN.CO), Roche (RHHBY) Drug Reduces Damage to Heart Muscle During Angioplasty
3/11/2013
More...
|
Trevena, Inc. to Present Results of TRV027 Phase 2a Study in Patients With Advanced Heart Failure
3/8/2013
More...
|
PRANA Biotechnology (PRAN) Details Data Showing That PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation
3/8/2013
More...
|
NeoStem, Inc. Reports Second Data Safety Monitoring Board Review: Continue With PreSERVE AMI Phase 2 Trial as Planned
3/7/2013
More...
|
Gilead Sciences, Inc. (GILD) Reveals Full 24-Week Phase 2 Results for HIV Regimen Containing TAF
3/6/2013
More...
|
ZIOPHARM Oncology, Inc. (ZIOP.OB) Announces Initiation of Indiana University-Sponsored Phase 2 Study of Palifosfamide in Recurrent and Incurable Germ Cell (Testicular and Ovarian) Tumors
3/6/2013
More...
|
Medivir AB (MVIRb.F) Release: Results From a Phase IIa Study Evaluating Simeprevir and Sofosbuvir in Prior Null Responder Hepatitis C Patients Have Been Presented at CROI
3/6/2013
More...
|
SymBio Pharmaceuticals Announces Completion of Patient Enrollment of TREAKISYM(R) (SyB L-0501) Phase II Trial in Frontline Low-Grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
3/6/2013
More...
|
Gilead Sciences, Inc. (GILD)-Medivir AB (MVIRb.F) Hepatitis C Drug Clears Virus in Patients
3/5/2013
More...
|
Tobira Therapeutics Inc. Presents Positive Phase 2b Clinical Results for Cenicriviroc in Treatment-Naïve HIV Infection in Late Breaker Session at CROI
3/5/2013
More...
|
Northwest Biotherapeutics (NWBT) Release: DCVax®-Direct Phase I/II Trial for All Inoperable Solid Tumors is Expected to Produce Ongoing Results in 2013
3/5/2013
More...
|
Oncolytics Biotech Inc. (ONC.TO) Completes Patient Enrollment in U.S. Phase 2 Study of REOLYSIN® in Non-Small Cell Lung Cancer
3/5/2013
More...
|
Cytomedix Inc. (CMXI) Announces Centers for Medicare & Medicaid Services Approval of Clinical Outcomes in Protocols for Autologous PRP (AutoloGel(™)) Under Coverage With Evidence Development Program
3/5/2013
More...
|
GlaxoSmithKline (GSK) DMD Drug Tied to Serious Side Effects, Hospitalizations
3/4/2013
More...
|
Chroma Therapeutics Release: Tosedostat Opal Study in Acute Myeloid Leukemia Published in Lancet Oncology
3/4/2013
More...
|
Argos Therapeutics, Inc. Validates Durability of AGS-003 Induced Immune Response in mRCC Patients
3/4/2013
More...
|
Vertex Pharmaceuticals (MA) (VRTX) Nails Mid-Stage Study for Influenza
3/4/2013
More...
|
PsiOxus Therapeutics Limited Completes Patient Enrollment for Phase II Wasting Disease Therapeutic MT-102
3/4/2013
More...
|
Cell Therapeutics, Inc. (CTIC) Release: Tosedostat OPAL Study in Acute Myeloid Leukemia Published in Lancet Oncology
3/4/2013
More...
|
PRANA Biotechnology (PRAN) Announces That PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation
3/4/2013
More...
|
Palatin Technologies (PTN) Presents Positive Data for Bremelanotide in Female Sexual Dysfunction
3/1/2013
More...
|
ADVENTRX Pharmaceuticals Inc. (ANX) to Develop ANX-188 for Complications of Arterial Disease
3/1/2013
More...
|
Trophos Announces Positive Interim Review in Pivotal Study of Olesoxime in Spinal Muscular Atrophy
2/28/2013
More...
|
Novan's SB204 Could Be First Topical Sebum Inhibitor
2/28/2013
More...
|
Neovasc Inc. (NVC)'s COSIRA Clinical Trial Protocol Selected for Publication in Peer-Reviewed Journal
2/28/2013
More...
|
CytRx Corporation (CYTR) Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial With Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer
2/28/2013
More...
|
Prima Biomed (PRR.AX) Commences "CANVAS" Clinical Trial in Europe
2/28/2013
More...
|
AbbVie (ABBV) Suspends Five Clinical Trials of Leukemia Therapy After Patient Deaths
2/27/2013
More...
|
Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN)' HerpV Phase 2 Study to Treat Genital Herpes Completes Enrollment
2/27/2013
More...
|
InViragen Advances DENVax into Second Stage of Ongoing Phase 2 Clinical Study
2/27/2013
More...
|
KaloBios Pharmaceuticals, Inc. Presents Clinical Results With Anti-GM-CSF Antibody in Persistent Asthma Data From KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Meeting
2/27/2013
More...
|
Kiadis Pharma Receives Regulatory Approval From Health Canada for a Phase II Clinical Study With Its Blood Cancer Treatment ATIR™
2/26/2013
More...
|
ADVENTRX Pharmaceuticals Inc. (ANX) Reviews Data Supporting Development of ANX-188 in New Indications
2/26/2013
More...
|
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 2 Study of ISIS-CRP Rx in Patients With Atrial Fibrillation
2/26/2013
More...
|
Boston Therapeutics, Inc. Reports Positive Phase ll Clinical Trial Results of PAZ320 in Patients With Type 2 Diabetes
2/26/2013
More...
|
Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
2/25/2013
More...
|